Safety profile of Sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes - an analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

被引：0
|
作者：
Maggioni, Aldo
Caterson, Ian
Coutinho, Walmir
Finer, Nick
Van Gaal, Luc
Sharma, Arya
Pedersen, Christian
James, W. Philip
机构：
[1] ANMCO Res Ctr, Florence, Italy
[2] Univ Sydney, Sydney, NSW 2006, Australia
[3] Catholic Univ, Rio De Janeiro, Brazil
[4] Univ Cambridge, Wellcome Trust Clin Res Facility, Cambridge CB2 1TN, England
[5] Univ Hosp, Antwerp, Belgium
[6] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[7] Bispebjerg Hosp, Copenhagen, Denmark
[8] London Sch Hyg & Trop Med, London WC1, England
来源：
INTERNATIONAL JOURNAL OF OBESITY | 2007年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S167 / S167
页数：1
相关论文
共 50 条
  • [21] Australian High-Risk Diabetic/CV Patients: Responses to 6-Weeks Sibutramine Treatment-A Preliminary Analysis of the SCOUT Trial
    Caterson, Ian
    Coutinho, Walmir
    Finer, Nick
    Maggioni, Aldo
    Sharma, Arya
    Torp-Pedersen, Christian
    Bacher, Peter
    James, W. Phillip T.
    OBESITY, 2008, 16 : S220 - S220
  • [22] Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial
    Andersson, Charlotte
    Weeke, Peter
    Fosbol, Emil Loldrup
    Brendorp, Bente
    Kober, Lars
    Coutinho, Walmir
    Sharma, Arya M.
    Van Gaal, Luc
    Finer, Nick
    James, W. Philip T.
    Caterson, Ian D.
    Rode, Richard A.
    Torp-Pedersen, Christian
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (08): : 1109 - 1115
  • [23] South and Central American High-Risk Diabetic/CV Patients: Responses after 6-Weeks Sibutramine Treatment - A Preliminary Analysis of the SCOUT Trial
    Coutinho, Walmir
    Caterson, Ian
    Finer, Nick
    Maggioni, Aldo
    Sharma, Arya
    Torp-Pedersen, Christian
    Bacher, Peter
    James, W. Phillip T.
    OBESITY, 2008, 16 : S219 - S219
  • [24] The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period
    Peter Weeke
    Charlotte Andersson
    Emil L Fosbøl
    Bente Brendorp
    Lars Køber
    Arya M Sharma
    Nick Finer
    Philip T James
    Ian D Caterson
    Richard A Rode
    Christian Torp-Pedersen
    BMC Endocrine Disorders, 10
  • [25] The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period
    Weeke, Peter
    Andersson, Charlotte
    Fosbol, Emil L.
    Brendorp, Bente
    Kober, Lars
    Sharma, Arya M.
    Finer, Nick
    James, Philip T.
    Caterson, Ian D.
    Rode, Richard A.
    Torp-Pedersen, Christian
    BMC ENDOCRINE DISORDERS, 2010, 10
  • [26] Prevalence and cardiovascular profile of metabolic syndrome in obese high-risk patients. An analysis from the SCOUT Trial
    Filardi, P. Perrone
    Urso, R.
    Chiariello, M.
    Maggioni, A. P.
    EUROPEAN HEART JOURNAL, 2009, 30 : 656 - 656
  • [27] Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease
    Aronow, Wilbert S.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1822 - 1825
  • [28] Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease
    Boehm, Michael
    Schumacher, Helmut
    Laufs, Ulrich
    Sleight, Peter
    Schmieder, Roland
    Unger, Thomas
    Teo, Koon
    Yusuf, Salim
    AMERICAN HEART JOURNAL, 2013, 166 (02) : 306 - +
  • [29] Educational Attainment Level and Risk of Mortality and Cardiopulmonary Outcomes in High-Risk Cardiovascular Disease Patients: The INVESTED Trial
    Lassen, Mats
    Howell, Nicholas
    Claggett, Brian
    Biering-Srensen, Tor
    Vardeny, Orly
    Solomon, Scott
    Udell, Jacob
    Joseph, Jacob
    Hegde, Sheila
    CIRCULATION, 2024, 150
  • [30] Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials
    Wang, Qian
    Liu, Lu
    Gao, Ling
    Li, Qiu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 34 - 42
12345